XML 31 R19.htm IDEA: XBRL DOCUMENT v3.25.1
Segment Information
 3 Months Ended
Mar. 31, 2025
Segment Reporting [Abstract]  
Segment Information Segment Information
The Company operates as one operating segment, the research and development of its investigational drug product. The Company used the management approach to determine its reportable operating segment. The Company's Chief Operating Decision Maker ("CODM") is its Chief Executive Officer, who reviews financial information presented on a consolidated basis. The Company is a clinical-stage pharmaceutical company and has limited revenue associated with a license and collaboration agreement. The CODM uses net loss as a measure of profit and loss, and assesses Company performance through the achievement of its clinical development goals. The CODM is regularly provided with budgeted and forecasted expense information which is used to determine the Company’s liquidity needs and cash allocation to its development programs. The CODM uses cash and marketable securities as a measure of segment assets in managing the enterprise.

The Company had no revenue during the three months ended March 31, 2025 and 2024. Depreciation and amortization expense was $43 thousand and $46 thousand for the three months ended March 31, 2025 and 2024, respectively. Equity method investment expense was $0 and $100 thousand for the three months ended March 31, 2025 and 2024, respectively.
The following table illustrates our segment information for significant operating expenses and includes a reconciliation to net loss for the three months ended March 31, 2025 and 2024:
 Three Months Ended March 31
 20252024
Operating Expenses:
Research and development by significant expense:
  BOLSTER trial$788 $1,270 
  ASCEND trial21 44 
  Chemistry, manufacturing and controls220 655 
  Clinical department1,156 1,133 
  Other (1)
417 139 
Research and development2,602 3,241 
General and administrative by significant expense:
  Corporate1,144 1,132 
  Investor relations/public relations/communications331 285 
  Finance629 580 
  Legal224 671 
  Business development127 172 
  Share based compensation expense404 368 
  Other (2)
386 152 
General and administrative3,245 3,360 
Operating loss(5,847)(6,601)
Other income, net161 402 
Benefit from income taxes(962)(798)
Net loss$(4,724)$(5,401)
Cash and marketable securities$25,833 $43,349 
 (1) Included in Other are the GBM study, FORTIFIDE study and research
     oncology expenses
 (2) Included in Other are facilities expense, human resource
     and information technology expenses